Abstract: Disclosed herein are methods for ranking tumor-specific neoantigens from a tumor of a subject that are suitable for subject-specific immunogenic compositions. Suitable tumor-specific neoantigens are tumor-specific neoantigens that are likely presented on the cell surface of the tumor, are likely to be immunogenic, are predicted to be expressed in sufficient amounts to elicit an immune response in the subject, optionally represent sufficient diversity across the tumor, and have relatively high manufacture feasibility. The present methods take a set of neoantigens (peptide vaccine candidates) and ranks the neoantigens in a way such that a group of top-ranked neoantigens simultaneously promotes cell-surface presentation of important neoantigens for Class I and Class II MHC molecules. The top-ranked neoantigens can then be further narrowed according manufacturability and/or other criteria.

Abstract: A thermoplastic polyurethane resin composition comprising: a thermoplastic polyurethane resin; an ultraviolet absorber package comprising a benzotriazole compound (UVA1), and a triazine compound (UVA2) wherein the mass ratio of UVA1 to UVA2 is from 1:1 to 3:1; optionally, a hindered amine light stabilizer and/or an antioxidant compound; and wherein the thermoplastic polyurethane resin composition has a maximum ultraviolet transmittance of ?3% in the wavelengths between 280 nm and 365 nm and an ultraviolet transmittance of ?6% in the wavelengths between 365 nm and 370 nm when the thermoplastic polyurethane resin is formed into a film having a thickness of 6 mils and wherein the cumulative weight % of UVA1 and UVA2 in the polyurethane resin composition ranges from 0.5 wt % to 0.85 wt % based on the total weight of the polyurethane resin composition.

Abstract: The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an agent that increases clearance of coagulation factors or platelets. Such an agent can be, for example, a neuraminidase.

Abstract: The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an agent that increases clearance of coagulation factors or platelets. Such an agent can be, for example, a neuraminidase.

Abstract: An active head restraint arrangement comprising a head restraint cushion, at least one head restraint post and head restraint post guide connecting said head restraint cushion to the interior of said passenger seats; and a flip-up assembly associated with said head restraint post beneath said head restraint cushion. Upon activation by rear impact, the flip-up assembly flips upward and forward to protect an occupant's head and neck from injury. Since this active head restraint arrangement utilizes a flip-up motion, the head restraint has a lower initial height that is dynamically increased upon activation. This feature allows the head restraint to be smaller allowing an occupant to have a better view around the head restraint.

Abstract: An active head restraint arrangement comprising a head restraint cushion, at least one head restraint post and head restraint post guide connecting said head restraint cushion to the interior of said passenger seats; and a flip-up assembly associated with said head restraint post beneath said head restraint cushion. Upon activation by rear impact, the flip-up assembly flips upward and forward to protect an occupant's head and neck from injury. Since this active head restraint arrangement utilizes a flip-up motion, the head restraint has a lower initial height that is dynamically increased upon activation. This feature allows the head restraint to be smaller allowing an occupant to have a better view around the head restraint.

Abstract: A vehicle seat and headrest assembly includes a seatback frame. A headrest assembly is provided and has a cushion portion and an impact target. The headrest assembly is rotatably connected to the seatback frame, wherein a rearward force applied upon the impact target causes the cushion portion to rotate upwardly and forwardly. A headrest assembly biasing member is operatively connected to the headrest assembly and the seatback frame and biases the headrest assembly against rotational movement. A locking mechanism is operatively connected to the headrest assembly and the seatback frame. The locking mechanism is movable between an unlocked position wherein the headrest assembly is permitted to rotate, and a locked position wherein the headrest assembly is prevented from rotating.